Featured Innovator

Head of Accenture's Houston innovation hub leads the charge for energy ingenuity

Brian Richards created Accenture's innovation hub before his clients even knew they needed it. Courtesy of Accenture

Brian Richards knew from his first college internship that, even as an engineer, he wasn't interested in a typical engineering position after college.

"The pace was slow and structures are rigorous — as they have to be," says Richards, managing director at Accenture's Houston office. "So, there's not much room for experimentation and innovation. I could tell that those were things that were going to excite me."

He found a position in Accenture's technology labs in Chicago that focused on spotting tech trends ahead of market demand. In 2011, he transitioned to energy innovation, noticing the potential for innovation in the energy industry, yet a lot of companies weren't focusing on new ways to do business more effectively.

Now, that's all changed, and Richards says he's seen an increased demand from energy companies seeking innovation projects.

Last year, Richards opened the doors to Accenture's innovation hub in Houston. The hub acts as a one-stop shop for Accenture clients looking for a new tool or better process to do something. Once Richards and his team find a solution for the client, Accenture is able to deploy its team of consultants to scale up that innovation to the entire company.

A steward for Houston innovation, Richards is on the board of Houston Exponential, the city-created innovation arm dedicated to making Houston optimized for innovation. With both of his HX and Accenture roles, he sees the same goals and ideas — from the need for resources to the need to execute plans.

"What we're trying to do in the city of Houston and within the innovation Hub are similar," Richards says. "Houston needs the right skillsets and mindsets, and we need the right skillsets and mindsets in our talent. You got to bring these people together, which we're doing in the city with the Innovation District, and what we did in our offices."

InnovationMap: You started developing ideas and processes for the innovation hub when you were still in Chicago, but when did you move to Houston?

Brian Richards: In 2015, I decided to move my family down to Houston to give it a real shot — we obviously wanted to build [the innovation hub] in Houston. I got approval in 2016, and we launched in February of 2017.

IM: Did your colleagues question your move to Houston?

BR: It was an odd path. Very few people in Chicago aspire to move into the energy industry. When I was looking at the potential in moving down for this, many of my friends told me to go to Austin or Silicon Valley and not to go to Houston — that's not where innovation is happening. On one hand, [at the time], they were right, but on the other hand, they definitely [ended up being] wrong. It's the fourth largest city, with energy and health industries booming. It makes all the sense in the world to try innovation in this city.

IM: What was the reception of the hub?

BR: I saw the innovation hub as something people didn't know they needed it until it was built — within both the market and within Accenture. Obviously, it was a big investment — it takes time, people, and space — and we were in the middle of an oil downturn, which isn't really a good time. But when it came to digital innovation, it was the right time and the right opportunity to make that investment. It took a lot of advocating, sponsorships, and ongoing support. When we look at repeat visits from clients who have been here a couple dozen times, that to me speaks to the demand and the experiences.

IM: Who are the innovation hub's clients?

BR: Most all fall within the resources — chemical, utilities, mining, oil and gas — range from all over the world. They come here because they are interested in what the market is doing. To develop your own innovation, you need different types of skills. These companies aren't able to have the teams of experts we have.

IM: What types of projects do you work on?

BR: All sorts of things, but I obviously can't talk about specific projects, but we organize our studio to have different domains. We have the data science team, which is focused on AI and things of that nature. We have an Industry X.0 cyber team, focused on automation and securing that. We have a design and engineering team. And then we focus on our platforms and partners as our last pillar.

Then, we use three core methodologies together: Design thinking, agile software delivery, and lean startup. Design thinking is putting the user at the center of what you're designing. Agile is running tests and workshops to ensure we're creating value. … They all fundamentally sit at the intersection of improving the business operations by bringing design capability and bringing developers to create the novel product. Then using the leverage and power of Accenture to scale that up.

IM: What does the scaling up process look like?

BR: Most of the time, if you're trying to do innovation, you're going to come up with ideas, use a whiteboard, concept, but it's usually going to have a mix of a different type of process or use of data. Any time you're doing something with new processes or something, there's risk inherent to that. Our innovation projects are designed around you not wanting to spend a bunch of money, because you don't know what you don't know until you start building it. So, we're very much focused on building it, and then when it works well at one plant, and they want to deploy it at 50 plants. Now, it's not about innovation, it's about the ability to deliver that across time zones and geography. That's where the rest of Accenture comes into play.

IM: What's next for innovation hub?

BR: The key for us is growth in general — we need to be able to support that demand we have. We are looking at our capabilities, the people and the skillsets we need, the facilities we need — we're looking at all of that.

IM: In the few years you've been here, how has Houston's innovation scene changed?

BR: I think it's pretty impressive. In 2016, was when we first got the innovation round table at the Greater Houston Partnership together. There were very passionate people in Houston for some time, so I don't want to make it sound like they finally came to their senses; that's not the case, people have been working on this for a long period time. But, what changed in 2016, was that it really hit at the institutional level of Houston — the mayor's office, GHP, Rice University. That's what led to the innovation strategy and to the commitment from leaders. We can't be the Energy Capital of the World or have the world's largest medical center and not have a focus on startups, venture capital, and more. We need that to maintain our superiority. Companies in Houston are growing these capabilities and working with different types of startups — if they can't find that here to improve their companies, they are going to go somewhere else. That was the major shift in 2016.

---

Portions of this interview have been edited.

Trending News

Building Houston

 
 

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Trending News